



*The Belgian Society for Toxicology and Ecotoxicology*

## **4th Workshop on Non-Clinical Safety Assessment of Biopharmaceuticals**

**“Bispecific antibodies and antibody-drug conjugates”**

**Friday 16 October 2015**

**Ablynx, Ghent, Belgium**

### **Programme**

8:30 – 9:00 Coffee

9:00 – 9:10 Welcome

#### **Morning session: Lectures**

9:10 – 9:55 Non-clinical considerations in the development of bispecific antibodies in inflammatory diseases  
B Schlereth, Covagen, Germany

9:55 – 10:40 Nonclinical assessment of Bispecific T cell-engaging Antibodies (BiTE®) and their transition into the clinic for anti-cancer therapy  
B Rattel, Amgen/Micromet, Germany

10:40 – 11:10 Coffee break

11:10 – 11:40 Bioanalytical considerations for bispecific antibodies and antibody-drug conjugates  
TBD

11:40 – 12:25 Nonclinical safety perspective on the development of Antibody-Drug-Conjugates  
D van den Dobbelaer, Synthron, The Netherlands

12:25 – 13:30 Lunch and networking

#### **Afternoon session: Case studies analysis**

13:30 – 13:45 Introduction to breakout sessions

13:45 – 14:50 Breakout sessions

14:50 – 15:05 Coffee break

15:05 – 16:20 Case study reporting and discussion

16:20 – 16:30 Concluding remarks

Organizing Committee: Judith Baumeister (Ablynx), Micaela Damsten, Frédérique Delannois and Lawrence Segal (GSK Vaccines), Miek Desmidt, Ad Knaapen and Ilham Smyej (Johnson & Johnson), Annick Cauvin and Miranda Cornet (UCB Pharma)

**Info and registration : [www.beltox.be](http://www.beltox.be)**